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Abstract
Glioblastoma (GBM) is the most aggressive primary brain tumor and thrives in a mi-
croenvironment of relative immunosuppression. The poor clinical outcome of these
malignant tumors requires the development of novel treatment options/therapeutic reg-
imens. Accordingly, numerous immunotherapies for GBM are currently being tested in
ongoing clinical trials. Herein we have examined the ability of the FDA approved drug
topotecan to suppress programmed death-ligand 1 (PD-L1) expression. Our results sug-
gest a role for topotecan as an adjuvant therapy in treatment regimens targeting certain
GBM patient subpopulations in whom the expression of PD-L1 has been conﬁrmed.
Introduction
Glioblastoma (GBM) is the most common and aggressive primary tumor intrinsic to
the central nervous system (CNS) being designated by the World Health Organization
(WHO) as a grade IV glioma [1] [2]. The prognosis remains dismal despite a multimodal
approach utilizing maximal surgical resection and adjuvant chemoradiation [3]. There-
fore, novel therapies are urgently needed to improve outcomes for patients with this
highly malignant neoplasm.
Evasion of the immune system is a hallmark of cancer, enabling tumor cells to escape
immune surveillance [4]. Accordingly, therapeutic activation of the immune system
through a variety of mechanisms is a rapidly expanding ﬁeld in oncology, and numerous
immune-activating agents have been approved by the FDA for cancer treatment over the
last several years [5]. GBM tumors create an immunosuppressive microenvironment
within the brain, resulting in both evasion of the body’s immune system and support of
the growth of cancer [6].
Cancer cells often express immune inhibitory signaling proteins that cause immune
cell dysfunction and/or apoptosis. One of these inhibitory molecules is programmed
death-ligand-1 (PD-L1), which binds to programmed death-1 (PD-1) expressed on T-
cells, B-cells, dendritic cells, and natural killer T-cells to suppress anti-cancer immunity
[7]. PD-L1 expression has been conﬁrmed in GBM cells [8] [9] and has been linked to
poor outcomes for GBM patients [10] [11]. It is prudent to note that PD-L1 expression
has also been reported on microglia/macrophages in GBM specimens [12] [13].
Immune checkpoint inhibition targeting PD-L1 or PD-1 has been found to increase re-
sponse rates in multiple cancer types [14] [15] [16] [17]. Considering the increasing
evidence that immune checkpoint blockade and other immunotherapy strategies lead
to sustained anti-tumor responses in several cancer types [18], there are increasingly
more immunotherapy trials evaluating checkpoint inhibitors in patients with glioblas-
toma [19].
Hypoxia, which induces the stability of the transcription factor hypoxia-inducible
factor-1-alpha (HIF-1α) is a common feature of solid tumors [20] [21] [22]. Interest-
ingly, recent reports have emerged demonstrating that HIF-1α can drive the expression
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of PD-L1 [23] [24], leading to immunesuppression and tumor evasion [7]. HIF-1α has
also been shown to trigger angiogenesis in gliomas [25]. Moreover, activation of EGFR
and downregulation of P53 and PTEN are seen in gliomas and have both been shown to
aﬀect HIF expression [26] [27] [28]. Of note, recent data show that chemotherapeutic
agents used for GBM treatment, such as the topoisomerase I inhibitor topotecan, might
have a suppressive eﬀect on HIF-1α [29] [30].
Until recently, it was unclear as to whether PD-L1 on tumor cells was suﬃcient for
tumor immune evasion or simply correlated with an inﬂamed/hypoxic tumor microen-
vironment. The elegant work of Juneja et al. has now established reduced CD8+ T-cell
cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immu-
nity [31]. Accordingly, we sought to use the FDA approved small molecular topotecan
to target the expression of PD-L1 in GBM in an eﬀort to ultimately enhance the eﬃcacy
of targeted immunotherapies for this intractable CNS neoplasm.
Objective
To explore a role for topotecan as an adjuvant therapy in treatment regimens target-
ing certain GBM patient subpopulations in whom the expression of PD-L1 has been
conﬁrmed.
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a
Figure Legend
Topotecan inhibits hypoxia-inducible factor 1-alpha (HIF-1α) and programmed
death-ligand-1 (PD-L1) in glioblastoma (GBM).
A. Treatment with 10 μM topotecan signiﬁcantly decreases levels of HIF1A, CD274, and
SLC2A1 mRNA transcripts in GBM cell line LN229. Expression fold change relative to
theDMSO control was quantiﬁed using the 2-ΔΔCT methodwithACTB as the endogenous
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control. Means +/- SD from N ≥ 3 independent experiments . **p<0.01, ***p<0.005,
****p<0.001.
B. Treatment with 10 μM topotecan signiﬁcantly decreases levels of HIF1A, CD274, and
SLC2A1 mRNA transcripts in the GBM cell line Mz18. Expression fold change rela-
tive to the DMSO control was quantiﬁed using the 2-ΔΔCT method with ACTB as the
endogenous control. Means +/- SD from N ≥ 3 independent experiments . **p<0.01,
****p<0.001.
C. Treatment with topotecan signiﬁcantly decreases levels of HIF-1α and PD-L1 protein
in GBM cell line LN229 at doses of 1 μM and 10 μM. Representative immunoblots are
shown. The bands corresponding toHIF-1α (~116-132 kDa) and PD-L1 (~40-50 kDa)were
cropped in each lane and the total intensities were measured in ImageJ, normalized to
the β-actin loading control, and expressed as a fold diﬀerence relative to the DMSO
control. Means +/- SD from N ≥ 3 independent experiments. ***p<0.005, ****p<0.001.
D. Treatment with topotecan signiﬁcantly decreases levels of HIF-1α and PD-L1 protein
in GBM patient cell line Mz18 at doses of 1 μM and 10 μM. Representative immunoblots
are shown. The bands corresponding to HIF-1α (~116-132 kDa) and PD-L1 (~40-50 kDa)
were cropped in each lane and the total intensities were measured in ImageJ, normalized
to the β-actin loading control, and expressed as a fold diﬀerence relative to the DMSO
control. Means +/- SD from N ≥ 3 independent experiments . **p<0.01, ***p<0.005.
E. The binding of PD-L1 to the cell surface receptor programmed cell death protein 1
(PD-1) suppresses CD8+ T-cell cytotoxicity and permits immune evasion in tumor cells;
topotecan inhibits PD-L1 expression.
Results & Discussion
Herein we conﬁrm that topotecan is an inhibitor of HIF-1α in two human GBM cell
lines, concordant with previous reports [29] [30]. Data obtained using topoisomerase
I-resistant cell lines and inactive camptothecin analogs suggest that the targeting of
topoisomerase I is critical to the inhibition of HIF-1α [32]. Since this eﬀect was abro-
gated via the interruption of RNA transcription [33], topotecan-induced perturbations
of HIF-1α may be occurring at the transcriptional level.
We therefore employed qPCR to determine whether the eﬀects of topotecan occurred
at the transcriptional level with regard to the reported decreases in HIF-1α, PD-L1, and
GLUT1 (a canonical target of HIF-1α) [34]. We show that topotecan signiﬁcantly de-
creased the expression of HIF1A, CD274, and SLC2A1 at a dose of 10 µM in both the
LN229 and Mz18 GBM cell lines (Figure A and B). To further investigate this eﬀect, we
conducted a dose-response study on HIF-1α and PD-L1 protein expression. We demon-
strated that topotecan signiﬁcantly decreases the expression of both HIF-1α and PD-L1
proteins at doses of 1 µM and 10 µM in both the LN229 and Mz18 GBM cell lines (Figure
C and D). Of note, such ﬁndings are in line with previous reports showing that HIF-1α is
capable of driving PD-L1 expression via binding to the hypoxia-response element (HRE)
located within the promoter of CD274, the gene encoding PD-L1 [7] [24] (Figure E).
HIF-1α activates the transcription of myriad genes that are involved in fundamental
aspects of cancer biology (e.g. angiogenesis, cell survival, glucose metabolism, and/or
invasion) [34]. Intratumoral hypoxia and genetic alterations can lead to HIF-1 overex-
pression, which has been associated with increased patient mortality in several cancer
types [34]. This is becoming particularly apparent in GBM, a tumor characterized by
pronounced areas of necrosis and hypoxia [20] [35]. Critically, our ﬁndings provide in-
sight into a novel function of the camptothecin derivative topotecan (i.e. an inhibitor
of HIF-1α and PD-L1) in glioblastoma cells. Further studies investigating the eﬀects of
topotecan-mediated downregulation of PD-L1 (with or without a combination of check-
point inhibitors) are needed to ultimately elucidate the clinical beneﬁt of such a novel
observation in GBM and other cancers.
Conclusions
Our ﬁndings suggest a role for topotecan as an adjuvant small molecule in immunother-
apy regimens in GBM (and/or other cancers in which HIF-1α and/or PD-L1 is expressed
by the tumor) as an agent that may enhance the eﬀect of immunomodulators such as
checkpoint inhibitors. The authors therefore contend that the data presented suggest
that repositioning topotecan may ultimately improve outcomes for GBM patients un-
dergoing immunotherapy. Accordingly, we will seek to further this work in relevant
animal models of GBM/immunotherapy.
Limitations
We understand and acknowledge that our work has limitations (i.e. we present solely
in vitro data). Further, we rely on the literature with regard to the translational value
which we assign our ﬁndings and remain uncertain if HIF-1α is the sole driver of PD-L1
expression within our GBM cell lines. However, we are conﬁdent in the observations
being put forward (i.e. topotecan decreased the levels of HIF-1α and PD-L1) and feel
they may ultimately be of translational value.
Our ﬁndings suggest a therapeutic role for the drug in GBM and other cancers, which
express PD-L1 (i.e. with the understanding that topotecan has FDA approval for the
treatment ovarian, cervical, and small cell lung cancers). It is therefore the authors’
contention that the data presented suggest that adjuvant therapy with topotecan (i.e.
drug repositioning) may ultimately improve outcomes for GBM patients undergoing im-
munotherapy. Accordingly, we will seek to further this work in relevant animal models
of GBM/immunotherapy.
Additional Information
Methods and Supplementary Material
Please see https://sciencematters.io/articles/201709000008.
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